Search hospitals > South Carolina > Greenville
Prisma Health Cancer Institute - Butternut
Claim this profileGreenville, South Carolina 29605
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
258 reported clinical trials
6 medical researchers
Summary
Prisma Health Cancer Institute - Butternut is a medical facility located in Greenville, South Carolina. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Prisma Health Cancer Institute - Butternut is involved with conducting 258 clinical trials across 433 conditions. There are 6 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Ki Chung, MDPrisma Health Cancer Institute - Eastside6 years of reported clinical research
Expert in Lung Cancer
Expert in Cancer
97 reported clinical trials
199 drugs studied
Aniket SahaBI-LO Charities Children's Cancer Center8 years of reported clinical research
Expert in Brain Tumor
Expert in Cancer
59 reported clinical trials
120 drugs studied
Jeffrey K. GiguerePrisma Health Cancer Institute - Faris8 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
26 reported clinical trials
64 drugs studied
Suzanne R. FanningPrisma Health Cancer Institute - Eastside2 years of reported clinical research
Studies Lymphoma
Studies Acute Myelogenous Leukemia
12 reported clinical trials
35 drugs studied
Clinical Trials running at Prisma Health Cancer Institute - Butternut
Lung Cancer
Breast Cancer
Breast cancer
Cancer
Colorectal Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Testicular cancer
Pancreatic Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Prisma Health Cancer Institute - Butternut?
Prisma Health Cancer Institute - Butternut is a medical facility located in Greenville, South Carolina. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Prisma Health Cancer Institute - Butternut is involved with conducting 258 clinical trials across 433 conditions. There are 6 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.